Six new medicines, including three orphan drugs for rare diseases, have been backed for European Union approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
An experimental therapy in development by Shire for patients with the rare blood disorder hereditary thrombotic thrombocytopenic purpura (hTTP) has been granted a fast track designation by the US Food and Drug Administration.
Almost three-quarters (73.2 percent) of local Clinical Commissioning Groups are failing to meet NHS England targets for improving children and young people’s mental health services (CAMHS), shows a new analysis by the Education Policy Institute.
Trusts are grappling with growing pressure from the top to increase savings in the approaching financial year, a survey by NHS Providers has revealed, just as three more are placed in financial special measures by the Care Quality Commission.
The National Institute for Health and Care Excellence has now published updated familial breast cancer guidelines which advocate the use of three medicines to reduce the risk of developing the disease.
Women who have taken the oral contraceptives seem have a reduced risk of developing some types of cancer for as long as thirty years, suggests new research from The University of Aberdeen, published in the American Journal of Obstetrics and Gynaecology.
The US Food and Drug Administration has approved the first novel treatment option in more than a decade for patients with Parkinson’s disease experiencing ‘off’ episodes while being treated with levodopa/carbidopa.